Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Metastatic Breast Cancer
and you are
over 20
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

The investigators address the clinical efficacy of continuing lapatinib treatment combined with vinorelbine after the progression of both trastuzumab and lapatinib treatment compared with vinorelbine alone in HER2 positive metastatic breast cancer patients.

Provided treatments

  • Drug: Lapatinib
  • Drug: Vinorelbine
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01730677. The sponsor of the trial is National Cancer Center, Korea and it is looking for 150 volunteers for the current phase.
Official trial title:
Randomized Phase II Study of Lapatinib Plus Vinorelbine Versus Vinorelbine in Patients With HER2 Positive Metastatic Breast Cancer Progressed After Lapatinib and Trastuzumab Treatment